Risk factors for early and late cholecystitis after covered metal stent placement for distal biliary obstruction.


Journal

Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 12 03 2023
received: 19 12 2022
accepted: 31 03 2023
medline: 23 10 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: ppublish

Résumé

Cholecystitis is a major adverse event after self-expandable metallic stent placement for distal biliary obstruction (DBO). Covered self-expandable metallic stent (CSEMS) is being increasingly used, but few studies have investigated risk factors for cholecystitis limited to CSEMS. The present study aimed to identify risk factors for cholecystitis after CSEMS. Patients who underwent initial CSEMS placement for DBO between November 2014 and September 2021 were enrolled and followed-up until death, recurrent biliary obstruction, cholecystitis, or until March 2022. Cholecystitis within 30 days of CSEMS was defined as early cholecystitis and after 30 days as late cholecystitis. Cholecystitis occurred in 51 of 339 patients (15%) after CSEMS. Forty-one patients (80.4%) had early cholecystitis, and 10 (19.6%) had late cholecystitis. Multivariate logistic regression analysis revealed that the maximum diameter of the common bile duct (CBD) (per 1 mm increase) (odds ratio [OR]: 0.87; 95% confidence interval [CI]: 0.76-1.00; p = .044), gallbladder stones (OR: 3.63; 95% CI: 1.62-8.10; p = .002), and tumor involvement in the cystic duct (CD) (OR: 4.87; 95% CI: 2.16-11.00; p < .001) were significant independent risk factors associated with early cholecystitis. No significant risk factors were identified for late cholecystitis. A smaller CBD diameter, gallbladder stones, and tumor involvement in the CD were identified as risk factors for early cholecystitis development after CSEMS.

Sections du résumé

BACKGROUND BACKGROUND
Cholecystitis is a major adverse event after self-expandable metallic stent placement for distal biliary obstruction (DBO). Covered self-expandable metallic stent (CSEMS) is being increasingly used, but few studies have investigated risk factors for cholecystitis limited to CSEMS. The present study aimed to identify risk factors for cholecystitis after CSEMS.
METHODS METHODS
Patients who underwent initial CSEMS placement for DBO between November 2014 and September 2021 were enrolled and followed-up until death, recurrent biliary obstruction, cholecystitis, or until March 2022. Cholecystitis within 30 days of CSEMS was defined as early cholecystitis and after 30 days as late cholecystitis.
RESULTS RESULTS
Cholecystitis occurred in 51 of 339 patients (15%) after CSEMS. Forty-one patients (80.4%) had early cholecystitis, and 10 (19.6%) had late cholecystitis. Multivariate logistic regression analysis revealed that the maximum diameter of the common bile duct (CBD) (per 1 mm increase) (odds ratio [OR]: 0.87; 95% confidence interval [CI]: 0.76-1.00; p = .044), gallbladder stones (OR: 3.63; 95% CI: 1.62-8.10; p = .002), and tumor involvement in the cystic duct (CD) (OR: 4.87; 95% CI: 2.16-11.00; p < .001) were significant independent risk factors associated with early cholecystitis. No significant risk factors were identified for late cholecystitis.
CONCLUSIONS CONCLUSIONS
A smaller CBD diameter, gallbladder stones, and tumor involvement in the CD were identified as risk factors for early cholecystitis development after CSEMS.

Identifiants

pubmed: 37698322
doi: 10.1002/jhbp.1350
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1180-1187

Informations de copyright

© 2023 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Références

Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut. 1994;35:467-470.
Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340:1488-1492.
Krokidis M, Fanelli F, Orgera G, Tsetis D, Mouzas I, Bezzi M, et al. Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol. 2011;34:352-361.
Kitano M, Yamashita Y, Tanaka K, Konishi H, Yazumi S, Nakai Y, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013;108:1713-1722.
Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, et al. A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction. Gut. 2004;53:729-734.
Dumonceau JM, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline - updated October 2017. Endoscopy. 2018;50:910-930.
Hu B, Sun B, Cai Q, Wong Lau JY, Ma S, Itoi T, et al. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. Gastrointest Endosc. 2017;86:44-58.
Seo DW, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, et al. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Gastrointest Endosc. 2019;90:602-612.
Jirapinyo P, AlSamman MA, Thompson CC. Impact of infected stent removal on recurrent cholangitis with time-to-event analysis. Surg Endosc. 2019;33:4109-4115.
Jung JH, Park SW, Hyun B, Lee J, Koh DH, Chung D. Identification of risk factors for obstructive cholecystitis following placement of biliary stent in unresectable malignant biliary obstruction: a 5-year retrospective analysis in single center. Surg Endosc. 2021;35:2679-2689.
Takinami M, Murohisa G, Yoshizawa Y, Shimizu E, Nagasawa M. Risk factors for cholecystitis after stent placement in patients with distal malignant biliary obstruction. J Hepatobiliary Pancreat Sci. 2020;27:470-476.
Nakai Y, Isayama H, Kawakubo K, Kogure H, Hamada T, Togawa O, et al. Metallic stent with high axial force as a risk factor for cholecystitis in distal malignant biliary obstruction. J Gastroenterol Hepatol. 2014;29:1557-1562.
Sogabe Y, Kodama Y, Honjo H, Aoyama I, Muramoto Y, Koga E, et al. Tumor invasion to the arteries feeding the gallbladder as a novel risk factor for cholecystitis after metallic stent placement in distal malignant biliary obstruction. Dig Endosc. 2018;30:380-387.
Watanabe M, Okuwaki K, Woo J, Kida M, Imaizumi H, Iwai T, et al. Cholecystitis after placement of covered self-expandable metallic stents in patients with distal malignant biliary obstructions. Clin Endosc. 2021;54:589-595.
Jang S, Stevens T, Parsi M, Lopez R, Zuccaro G, Dumot J, et al. Association of covered metallic stents with cholecystitis and stent migration in malignant biliary stricture. Gastrointest Endosc. 2018;87:1061-1070.
Isayama H, Kawabe T, Nakai Y, Tsujino T, Sasahira N, Yamamoto N, et al. Cholecystitis after metallic stent placement in patients with malignant distal biliary obstruction. Clin Gastroenterol Hepatol. 2006;4:1148-1153.
Ainley CC, Williams SJ, Smith AC, Hatfield AR, Russell RC, Lees WR. Gallbladder sepsis after stent insertion for bile duct obstruction: management by percutaneous cholecystostomy. Br J Surg. 1991;78:961-963.
Miura F, Okamoto K, Takada T, Strasberg SM, Asbun HJ, Pitt HA, et al. Tokyo guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018;25:31-40.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-458.
Satoh T, Ishiwatari H, Kawaguchi S, Shirane N, Matsubayashi H, Kaneko J, et al. Comparing the 14-mm uncovered and 10-mm covered metal stents in patients with distal biliary obstruction caused by unresectable pancreatic cancer: a multicenter retrospective study. Surg Endosc. 2022;36:736-744.
Podboy A, Yuan J, Stave CD, Chan SM, Hwang JH, Teoh AYB. Comparison of EUS-guided endoscopic transpapillary and percutaneous gallbladder drainage for acute cholecystitis: a systematic review with network meta-analysis. Gastrointest Endosc. 2021;93(4):797-804.
Luo X, Sharaiha R, Teoh AYB. Endoscopic management of acute cholecystitis. Gastrointest Endosc Clin N Am. 2022;32(3):527-543.
Ishii T, Kin T, Yamazaki H, Hama K, Nakamura R, Iwano K, et al. Prophylactic endoscopic gallbladder stenting for cholecystitis after covered metal stent placement for distal biliary obstruction. Gastrointest Endosc. 2023;98(1):36-42.

Auteurs

Tatsuya Ishii (T)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Tsuyoshi Hayashi (T)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Hajime Yamazaki (H)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Risa Nakamura (R)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Kosuke Iwano (K)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Ryo Ando (R)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Haruka Toyonaga (H)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Toshifumi Kin (T)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Kuniyuki Takahashi (K)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Akio Katanuma (A)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH